FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283695814> ?p ?o ?g. }

• W4283695814 endingPage "797" @default.
• W4283695814 startingPage "796" @default.
• W4283695814 abstract "Background Current knowledge on the health status of patients (pts.) with axial spondyloarthritis (axSpA) mainly focusses on physical function and disease activity. Using a generic measure for physical- or mental health (SF36), a hierarchical relationship between disease activity, spinal damage, spinal mobility, physical function and overall health has been demonstrated in pts. with radiographic axSpA (r-axSpA) 1 . Disease-specific global functioning and health can be assessed in pts. with axSpA using the ASAS Health Index (ASAS HI), which encompasses physical function, as well as aspects of emotional and social functioning and aspects of activity and participation. Objectives To build a structural model that visualizes interrelationships of different patient- and disease characteristics with global functioning and health in pts. with early axSpA. Methods Data of pts. with axSpA from the DESIR cohort was analyzed, which included information on socio-demographics (age, BMI), disease activity (ASDAS), physical function (BASFI), spinal mobility (BASMI), structural damage (mSASSS), disease-specific global functioning (ASAS HI), and comorbidity count. Information on patient- and disease characteristics was retrieved from the visit performed 72 months after inclusion, which was the first time point of ASAS HI collection. A Bayesian network (BN) was used to obtain insight of the underlying structural model. BNs are probabilistic graphical models consisting of “nodes” (representing specific variables) joined by “edges” (lines representing directions of effects). They are capable of capturing complex relationships between variables and allow the incorporation of existing (prior) knowledge from previous studies. Results The DESIR cohort contained data from 582 pts. at month 72, of whom 398 had data for ASAS HI. Descriptive information of these pts. is shown in Table 1. The mean ASAS HI was 5.7 (range: 0 - 16). Applying existing cut-offs for ASAS HI, 51% had ‘good’ global functioning (ASAS HI ≥5), 40% had ‘moderate’ global functioning (5< ASAS HI <12) and 9% had ‘bad’ global functioning (ASAS HI ≥12). The structural model that was constructed from combining data and prior expert knowledge is visualized in Figure 1. It suggests that ASDAS and BASFI have a direct impact on ASAS HI and that ASDAS has an indirect impact via BASFI. The model also suggests that ASDAS has an impact on the number of co-morbidities via BMI and that BASFI determines BASMI, which is in turn also influenced by age and mSASSS. In addition, it suggests a direct effect of age, BMI and ASAS HI on the comorbidity count. The model denies a relationship between BASMI or mSASSS and ASAS HI. Table 1. Patient and disease characteristics at month 72 N = 398 Gender (male), N (%) 181 (45%) Age (years) 40.7 (8.7) Symptom duration (years) 7.5 (0.9) BMI (kg/m 2 ) 25.0 (4.6) ASDAS 2.0 (1.0) BASFI (0–10) 2.3 (2.1) BASMI (0–10) 2.5 (1.0) mSASSS (0-72) 1.0 (3.6) ASAS HI (0-17) 5.7 (3.9) good global functioning: ASAS HI ≤5, N (%) 201 (51%) moderate global functioning: 5< ASAS HI <12, N (%) 160 (40%) bad global functioning: ASAS HI ≥12, N (%) 37 (9%) Comorbidity count 1.4 (0.7) Figure 1. Structural model on interrelationships of different patient- and disease characteristics with global functioning and health (ASAS HI) in patients with early axSpA Conclusion The BN-analysis approach, that combines prior knowledge and measured data, serves to better understand the construct of global functioning and health in pts. with early axSpA. Our model shows that global functioning (ASAS-HI) is determined both by patient-reported physical function (BASFI) and by disease activity (ASDAS), which confirms the hierarchical model once proposed by Machado et al. The observed directional relationship between ASAS HI and comorbidity count is counterintuitive and requires further investigation. References [1]Machado P, ARD 2011. Disclosure of Interests Imke Redeker: None declared, Robert B.M. Landewé Speakers bureau: AbbVie, BMS, GSK Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, UCB, Consultant of: AbbVie, BMS, GSK Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, UCB, Désirée van der Heijde Speakers bureau: AbbVie, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Lilly, Novartis, Pfizer, UCB Pharma, Consultant of: AbbVie, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Lilly, Novartis, Pfizer, UCB Pharma, Grant/research support from: AbbVie, Bayer, BMS, Cyxone, Eisai, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Lilly, Novartis, Pfizer, UCB Pharma, Sofia Ramiro Speakers bureau: Eli Lilly, MSD, Novartis, UCB, Consultant of: AbbVie, Eli Lilly, MSD, Novartis, UCB, Sanofi, Grant/research support from: AbbVie, Galapagos, Novartis, Pfizer, UCB, Annelies Boonen Speakers bureau: Abbvie / Galapagos, Consultant of: Galapagos, Grant/research support from: Abbvie, Maxime Dougados: None declared, Juergen Braun Speakers bureau: Abbvie, Amgen, Biogen, BMS, Boehringer, Celltrion, Chugai, Fresenius, Hexal, Janssen, Lilly, Medac, MSD, Mylan, Mundipharma, Novartis, Pfizer und UCB, Consultant of: Abbvie, Amgen, Biogen, BMS, Boehringer, Celltrion, Chugai, Fresenius, Hexal, Janssen, Lilly, Medac, MSD, Mylan, Mundipharma, Novartis, Pfizer und UCB, Grant/research support from: Abbvie, Amgen, Biogen, BMS, Boehringer, Celltrion, Chugai, Fresenius, Hexal, Janssen, Lilly, Medac, MSD, Mylan, Mundipharma, Novartis, Pfizer und UCB, Uta Kiltz Speakers bureau: AbbVie, Biocad, Biogen, Chugai, Eli Lilly, Hexal, Janssen, MSD, Novartis, Pfizer, Roche, UCB, Consultant of: AbbVie, Biocad, Biogen, Chugai, Eli Lilly, Hexal, Janssen, MSD, Novartis, Pfizer, Roche, UCB, Grant/research support from: AbbVie, Biogen, Fresenius, Amgen, Hexal, Novartis, Pfizer" @default.
• W4283695814 created "2022-06-30" @default.
• W4283695814 creator A5005585783 @default.
• W4283695814 creator A5006289570 @default.
• W4283695814 creator A5015176926 @default.
• W4283695814 creator A5016383516 @default.
• W4283695814 creator A5026338300 @default.
• W4283695814 creator A5075171185 @default.
• W4283695814 creator A5077598725 @default.
• W4283695814 creator A5078117566 @default.
• W4283695814 date "2022-05-23" @default.
• W4283695814 modified "2023-09-26" @default.
• W4283695814 title "POS0976 IMPACT OF PATIENT AND DISEASE CHARACTERISTICS ON GLOBAL FUNCTIONING AND HEALTH IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: A BAYESIAN NETWORK ANALYSIS OF DATA FROM AN EARLY axSpA COHORT" @default.
• W4283695814 doi "https://doi.org/10.1136/annrheumdis-2022-eular.2318" @default.
• W4283695814 hasPublicationYear "2022" @default.
• W4283695814 type Work @default.
• W4283695814 citedByCount "0" @default.
• W4283695814 crossrefType "journal-article" @default.
• W4283695814 hasAuthorship W4283695814A5005585783 @default.
• W4283695814 hasAuthorship W4283695814A5006289570 @default.
• W4283695814 hasAuthorship W4283695814A5015176926 @default.
• W4283695814 hasAuthorship W4283695814A5016383516 @default.
• W4283695814 hasAuthorship W4283695814A5026338300 @default.
• W4283695814 hasAuthorship W4283695814A5075171185 @default.
• W4283695814 hasAuthorship W4283695814A5077598725 @default.
• W4283695814 hasAuthorship W4283695814A5078117566 @default.
• W4283695814 hasBestOaLocation W42836958141 @default.
• W4283695814 hasConcept C115219716 @default.
• W4283695814 hasConcept C119857082 @default.
• W4283695814 hasConcept C126322002 @default.
• W4283695814 hasConcept C1862650 @default.
• W4283695814 hasConcept C2776213234 @default.
• W4283695814 hasConcept C2776260265 @default.
• W4283695814 hasConcept C2777402515 @default.
• W4283695814 hasConcept C2777453003 @default.
• W4283695814 hasConcept C2778579456 @default.
• W4283695814 hasConcept C2778818304 @default.
• W4283695814 hasConcept C2779134260 @default.
• W4283695814 hasConcept C2780415856 @default.
• W4283695814 hasConcept C33724603 @default.
• W4283695814 hasConcept C41008148 @default.
• W4283695814 hasConcept C71924100 @default.
• W4283695814 hasConcept C72563966 @default.
• W4283695814 hasConceptScore W4283695814C115219716 @default.
• W4283695814 hasConceptScore W4283695814C119857082 @default.
• W4283695814 hasConceptScore W4283695814C126322002 @default.
• W4283695814 hasConceptScore W4283695814C1862650 @default.
• W4283695814 hasConceptScore W4283695814C2776213234 @default.
• W4283695814 hasConceptScore W4283695814C2776260265 @default.
• W4283695814 hasConceptScore W4283695814C2777402515 @default.
• W4283695814 hasConceptScore W4283695814C2777453003 @default.
• W4283695814 hasConceptScore W4283695814C2778579456 @default.
• W4283695814 hasConceptScore W4283695814C2778818304 @default.
• W4283695814 hasConceptScore W4283695814C2779134260 @default.
• W4283695814 hasConceptScore W4283695814C2780415856 @default.
• W4283695814 hasConceptScore W4283695814C33724603 @default.
• W4283695814 hasConceptScore W4283695814C41008148 @default.
• W4283695814 hasConceptScore W4283695814C71924100 @default.
• W4283695814 hasConceptScore W4283695814C72563966 @default.
• W4283695814 hasIssue "Suppl 1" @default.
• W4283695814 hasLocation W42836958141 @default.
• W4283695814 hasOpenAccess W4283695814 @default.
• W4283695814 hasPrimaryLocation W42836958141 @default.
• W4283695814 hasRelatedWork W2269745855 @default.
• W4283695814 hasRelatedWork W2554544265 @default.
• W4283695814 hasRelatedWork W2755939016 @default.
• W4283695814 hasRelatedWork W2911716870 @default.
• W4283695814 hasRelatedWork W2952182196 @default.
• W4283695814 hasRelatedWork W3042395162 @default.
• W4283695814 hasRelatedWork W3095085666 @default.
• W4283695814 hasRelatedWork W3163961032 @default.
• W4283695814 hasRelatedWork W3165479055 @default.
• W4283695814 hasRelatedWork W4283695814 @default.
• W4283695814 hasVolume "81" @default.
• W4283695814 isParatext "false" @default.
• W4283695814 isRetracted "false" @default.
• W4283695814 workType "article" @default.